Who are Tazarotene (Actavis)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sohonos, TRIFAROTENE, Targretin, Panretin, Differin, Soriatane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tazarotene-actavis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tazarotene (Actavis) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tazarotene (Actavis) (Tazarotene (Actavis)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid. Area: Dermatology.

phase 3 Retinoid Retinoid X Receptor (RXR), Retinoid Acid Receptor (RAR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Tazarotene (Actavis) (Tazarotene (Actavis)) — Actavis Inc.. Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tazarotene (Actavis) TARGET	Tazarotene (Actavis)	Actavis Inc.	phase 3	Retinoid	Retinoid X Receptor (RXR), Retinoid Acid Receptor (RAR)
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
TRIFAROTENE	TRIFAROTENE		marketed	Retinoid [EPC]		2019-01-01
Targretin	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01
Soriatane	ACITRETIN	Stiefel Labs Inc	marketed	Retinoid [EPC]	Bile salt export pump	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-09-15 — Differin · 8435502 · Formulation · US
2026-09-15 — Differin · 8709392 · Formulation · US
2028-05-31 — Differin · 7998467 · Formulation · US

Sponsor landscape (Retinoid class)

Galderma R&D · 8 drugs in this class
Bausch Health Americas, Inc. · 4 drugs in this class
Stiefel, a GSK Company · 2 drugs in this class
Army Medical University, China · 1 drug in this class
Centro Dermatológico Dr. Ladislao de la Pascua · 1 drug in this class
Cipher Pharmaceuticals Inc. · 1 drug in this class
Center for Sight Las Vegas · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Dr.dr.Irma Bernadette, SpKK (K) · 1 drug in this class
Dr. Emmy Graber · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tazarotene (Actavis) — Competitive Intelligence Brief. https://druglandscape.com/ci/tazarotene-actavis. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab